S34 - Haematological Disorder and Lungs
By Yong Kek, Pang
Following allogeneic haematopoietic stem cell transplantation (alloHSCT), pulmonary graft-versus-host disease (pGVHD) represents a serious complication driven by alloreactive donor immune cells, conditioning therapies, and infections. Acute manifestations present within 100 days primarily as pneumonia or bronchitis, whereas chronic pGVHD manifests beyond 100 days as bronchiolitis obliterans syndrome (BOS), interstitial lung disease (ILD), or rare vascular complications. Chronic pGVHD has an estimated cumulative incidence of ~20% within two years post-transplant, with BOS accounting for 56.4% and ILD for 30.8% of non-infectious complications.
Because clinical onset is often indolent—and many patients are identified only after 40% to 50% of lung function is lost—early detection through structured surveillance is essential to prevent progressive, irreversible injury. Surveillance protocols recommend baseline and routine spirometry at 3 months, 6 months, and annually for 2 years post-transplant, with accelerated testing after acute flares or immunosuppression tapering. Patients with chronic pGVHD warrant spirometry at least every 6 months and annual full pulmonary function testing. Complementary assessments, including high-resolution CT (HRCT), 6-minute walk tests, and multidisciplinary reviews, are critical to exclude alternative pathologies and guide therapy.